At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.
We ar... more >
Bellerophon (Nasdaq: BLPH)
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
|WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2017.
“We continue to achieve important progress in all three of our INOpulse® clinical development programs,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. “In our INOvation-1 Phase 3 trial for Pulmonary Arterial Hyperten... |
Bellerophon Announces $23 Million Private Placement
|Financing will support the continued development of the company’s INOpulse platform with Phase 3 clinical trials in Pulmonary Arterial Hypertension and Phase 2 trials in Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) and Pulmonary Hypertension associated with COPD
WARREN, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities p... |
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
|WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
Rodman & Renshaw 19th Annual Global Investment Conference
Tuesday, September ... |
|There are currently no events scheduled.|